Search results
Results From The WOW.Com Content Network
Infliximab. Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. [ 23]
Janssen Pharmaceuticals was the first Western pharmaceutical company to set up a pharmaceutical factory in the People's Republic of China. [27] In 1976, Paul Janssen met Ma Haide (born George Shafik Hatem), a Lebanese-American doctor who had started working in China in 1933. After three days of meetings, the two agreed to bring a modernized ...
Jan T. Vilček (born June 17, 1933) is a Slovak-American biomedical scientist, educator, inventor and philanthropist. He is a professor in the department of microbiology at the New York University School of Medicine, [1] and chairman and CEO of The Vilcek Foundation. [2] Vilček received his M.D. degree from Comenius University Medical School ...
The personal information was part of a database used on the Janssen CarePath platform, according to IBM. IBM, which manages the database, said it was unable to determine the extent of the ...
For 129 years, New Brunswick has served as the headquarters of J&J, America’s seventh most valuable public company. With consumer products from Band-Aids to baby powder, Neutrogena to Rogaine, Listerine to Visine, Aveeno to Tylenol and Sudafed to Splenda, Johnson & Johnson is the biggest and, according to multiple surveys, most admired ...
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [ 8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8] It is taken by mouth.
Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) is a subsidiary of Johnson & Johnson that is responsible for discovering and developing pharmaceutical drugs. J&JPRD has research sites located in Raritan, New Jersey, Titusville, New Jersey, Spring House, Pennsylvania, La Jolla, California, Beerse, Belgium and Toledo, Spain .
JNJ-42165279. JNJ-42165279 is a drug developed by Janssen Pharmaceutica which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC 50 of 70 nM. [1] It is described as a covalently binding but slowly reversible selective inhibitor of FAAH. [2]